Testing a low-dose pneumonia vaccine with a new booster
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests a new pneumonia vaccine called PCV-LITE, which uses a lower dose and a special booster (adjuvant). It aims to see if the vaccine is safe and helps your immune system fight pneumonia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 50 years old.
- You are in good general health, with a BMI between 18.5 and 35.
- If you are a woman of childbearing age, you must use reliable birth control starting 1 month before and continuing for 3 months after the vaccine, and not be pregnant or breastfeeding.
- You have not had a lab-confirmed pneumonia infection in the last 3 years.
- You do not have a serious immune disorder, bleeding issues, or history of severe allergic reactions to vaccine components.
- You have not received a pneumonia vaccine or certain other vaccines in the past month, and are not in another clinical trial.
- You do not take strong immune-suppressing drugs or more than one blood thinner, and you do not have unstable medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational vaccine that may protect infants against infections caused by a bacteria called Streptococcus pneumoniae, which can cause pneumonia and other serious illnesses. The vaccine is given to healthy babies around 2 months old, and the study will see how well it works and how safe it is.
This study tests a new pneumococcal vaccine (PCV15) to see how well it protects against carrying the bacteria that can cause pneumonia. Healthy adults aged 18–50 who have not had a pneumococcal vaccine in the last 5 years may join.
This trial tests a new 23-valent pneumococcal vaccine to see if it safely protects healthy people against pneumonia and other infections caused by pneumococcal bacteria.
This study tests a new vaccine that protects against 21 types of bacteria that cause pneumonia and other infections. It is for healthy infants around 2 months old to see if it works as well as the current vaccine.
This study tests an experimental pneumococcal vaccine in healthy infants. It involves three shots during infancy and a booster around 12-15 months to see if it is safe and how the body responds.
This study tests a new pneumococcal vaccine (PCV24) for babies ages 2 to 23 months. It aims to see if the vaccine is safe and helps protect against serious infections like pneumonia and meningitis.
Hear when a new Vaccine Reaction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.